- NuGen Medical Devices (NGMD) has shared results from recent studies of its needle-free injection device, InsuJet
- Independent studies confirmed that InsuJet provides up to 40 per cent faster insulin uptake in diabetic patients versus needle injections
- NuGen is a medical device company developing needle-free technologies and other medical delivery products
- Nugen Medical Devices Inc. (NGMD) opened trading at C$0.195
NuGen Medical Devices (NGMD) has shared results from recent studies of its needle-free injection device, InsuJet.
Studies performed at the Radboud University Medical Center in Nijmegen, Netherlands, confirmed that InsuJet provides up to 40 per cent faster insulin uptake in diabetic patients compared to needle injections.
Many patients confirm they notice faster insulin absorption with InsuJet.
“Data from our past clinical studies, patient testimonials and feedback confirm the benefits of this faster absorption which is bringing many positive benefits to diabetes management. The majority of patients confirm noticeably faster absorption,” commented Mr. Nicky Canton, Chief Operation Officer of NuGen.
“Time and again, we hear that for both children and adults with an active lifestyle InsuJet, with its needle-free injection delivery and its quick insulin absorption, has contributed immensely in the management of their diabetes care.”
Richard Buzbuzian, President & CEO, added,
“NuGen has become invigorated with a group of like-minded individuals committed to investing time and capital to improve life for millions of diabetics worldwide.”
About NuGen Medical Devices
NuGen is a medical device company developing needle-free technologies and other medical delivery products. The company’s products include the InsuJet and PetJet needle-free injection systems.
Nugen Medical Devices Inc. (NGMD) opened trading at C$0.195.